Table 2 Adverse events with TDM1 observed in the study.

From: Real-world data on trastuzumab emtansine (TDM1) efficacy and safety: Results of a single-centre retrospective study of HER2-positive metastatic breast cancer patients

Adverse Event

Any Grade

Grade 3–4

Elevated Transaminases

18 (25.7%)

6 (8.5%)

Thrombocytopenia

11 (15.7%)

4 (5.7%)

Anemia

8 (11.4%)

3 (4.2%)

Neutropenia

5 (7.1%)

1 (1.4%)

Hypokalemia

6 (8.5%)

1 (1.4%)

Back to article page